Oruka Therapeutics Inc.
Organization details
- Legal name
- Oruka Therapeutics Inc.
- Former names
- ARCA biopharma, Inc. Nuvelo Inc Hyseq Inc
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Menlo Park
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- ORKA
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0000907654
- EIN
- 36-3855489
Board of directors
-
Anders D. Hove · DirectorSince 2024
-
Cameron Turtle · DirectorSince 2024
-
Carl Dambkowski · DirectorSince 2024
-
Christopher Nathan Martin · DirectorSince 2025
-
Daniel J. Mitchell · DirectorSince 2024
-
Jacob Ma-Weaver · DirectorSince 2024
-
James P. Flynn · DirectorSince 2024
-
Kristine M. Ball · DirectorSince 2024
-
Lawrence Otto Klein · Director · Chief Executive OfficerSince 2024
-
Linda Grais · DirectorSince 2024
- Since 2024
-
Raymond L. Woosley · DirectorSince 2024
-
Robert E. Conway · DirectorSince 2024
-
Samarth Kulkarni · DirectorSince 2024
- Since 2024
Chief executives
Director election results
Annual meeting of June 2, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
99.9%
-
99.9%
Board connections
9 of this board's directors also sit on 18 other boards. 18 are in the same sector.
-
Jade Biosciences Inc. Same sectorvia Lawrence Otto Klein, Peter Evan Harwin and Tomas Kiselak
-
Spyre Therapeutics Inc. Same sectorvia Cameron Turtle, Peter Evan Harwin and Tomas Kiselak
-
Crescent Biopharma Inc. Same sectorvia Peter Evan Harwin and Tomas Kiselak
-
Damora Therapeutics Inc. Same sectorvia Cameron Turtle and Peter Evan Harwin
-
Dianthus Therapeutics Inc. Same sectorvia Peter Evan Harwin and Tomas Kiselak
-
Korsana Biosciences Inc. Same sectorvia Peter Evan Harwin and Tomas Kiselak
-
Viridian Therapeutics Inc. Same sectorvia Peter Evan Harwin and Tomas Kiselak
-
Zenas BioPharma Inc. Same sectorvia Peter Evan Harwin and Tomas Kiselak
-
Achieve Life Sciences Inc. Same sectorvia Christopher Nathan Martin
-
Black Diamond Therapeutics Inc. Same sectorvia Samarth Kulkarni
-
CRISPR Therapeutics AG Same sectorvia Samarth Kulkarni
-
Cogent Biosciences Inc. Same sectorvia Peter Evan Harwin
-
Corvus Pharmaceuticals Inc. Same sectorvia Linda Grais
-
Edgewise Therapeutics Inc. Same sectorvia Christopher Nathan Martin
-
Enliven Therapeutics Inc. Same sectorvia Kristine M. Ball
-
ICON plc Same sectorvia Linda Grais
-
Jasper Therapeutics Inc. Same sectorvia Lawrence Otto Klein
-
Lite Strategy Inc. Same sectorvia James P. Flynn
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $339,541,582
- 122 sales by 7 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Nov 2, 2026 | Lawrence Otto Klein Director, Officer (Chief Executive Officer) | Option exercise | +25,000 | $7.80 | $195,000 |
| Nov 2, 2026 | Lawrence Otto Klein Director, Officer (Chief Executive Officer) | Open-market sale | −6,466 | $94.77 | $612,794 |
| Nov 2, 2026 | Lawrence Otto Klein Director, Officer (Chief Executive Officer) | Open-market sale | −15,036 | $95.64 | $1,437,987 |
| Nov 2, 2026 | Lawrence Otto Klein Director, Officer (Chief Executive Officer) | Open-market sale | −2,442 | $96.70 | $236,147 |
| Nov 2, 2026 | Lawrence Otto Klein Director, Officer (Chief Executive Officer) | Open-market sale | −756 | $97.45 | $73,676 |
| Nov 2, 2026 | Lawrence Otto Klein Director, Officer (Chief Executive Officer) | Open-market sale | −300 | $98.40 | $29,521 |
| Oct 20, 2026 | Quinlan Paul T Officer (General Counsel) | Option exercise | +9,000 | $7.80 | $70,200 |
| Oct 20, 2026 | Quinlan Paul T Officer (General Counsel) | Open-market sale | −400 | $74.90 | $29,960 |
| Oct 20, 2026 | Quinlan Paul T Officer (General Counsel) | Open-market sale | −500 | $76.12 | $38,059 |
| Oct 20, 2026 | Quinlan Paul T Officer (General Counsel) | Open-market sale | −1,000 | $77.21 | $77,205 |
| Oct 20, 2026 | Quinlan Paul T Officer (General Counsel) | Open-market sale | −4,100 | $78.79 | $323,037 |
| Oct 20, 2026 | Quinlan Paul T Officer (General Counsel) | Open-market sale | −3,000 | $79.49 | $238,474 |
| Oct 12, 2026 | Agarwal Arjun Officer (Senior Vice President, Finance) | Option exercise | +8,541 | $12.50 | $106,763 |
| Oct 12, 2026 | Agarwal Arjun Officer (Senior Vice President, Finance) | Option exercise | +1,458 | $34.39 | $50,141 |
| Oct 12, 2026 | Agarwal Arjun Officer (Senior Vice President, Finance) | Open-market sale | −5,741 | $80.03 | $459,453 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Oruka Therapeutics Inc.
Who is the CEO of Oruka Therapeutics Inc.?
Lawrence Otto Klein has been Oruka Therapeutics Inc.'s President and CEO since August 2024.
How many directors are on Oruka Therapeutics Inc.'s board?
Oruka Therapeutics Inc.'s board has 15 directors: Anders D. Hove, Cameron Turtle, Carl Dambkowski, Christopher Nathan Martin, Daniel J. Mitchell, Jacob Ma-Weaver, James P. Flynn, Kristine M. Ball, Lawrence Otto Klein, Linda Grais and 5 others.
Are Oruka Therapeutics Inc. insiders buying or selling shares?
Over the last 12 months, Oruka Therapeutics Inc. insiders made no open-market purchases and sold $339.5 million of shares in 122 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="oruka-therapeutics-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.